Novo Nordisk A/S (NVO)
39.05
-0.38
(-0.96%)
USD |
NYSE |
Oct 23, 16:00
39.01
-0.04
(-0.10%)
Pre-Market: 20:00
Novo Nordisk Price to Book Value : 5.101 for Oct. 23, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 5.101 |
| October 22, 2026 | 5.150 |
| October 21, 2026 | 5.102 |
| October 20, 2026 | 5.140 |
| October 19, 2026 | 5.018 |
| October 16, 2026 | 5.072 |
| October 15, 2026 | 5.123 |
| October 14, 2026 | 4.979 |
| October 13, 2026 | 4.971 |
| October 12, 2026 | 5.039 |
| October 09, 2026 | 5.047 |
| October 08, 2026 | 4.987 |
| October 07, 2026 | 4.998 |
| October 06, 2026 | 4.902 |
| October 05, 2026 | 4.903 |
| October 02, 2026 | 4.875 |
| October 01, 2026 | 4.885 |
| September 30, 2026 | 4.952 |
| September 29, 2026 | 5.004 |
| September 28, 2026 | 5.056 |
| September 25, 2026 | 5.068 |
| September 24, 2026 | 5.044 |
| September 23, 2026 | 4.986 |
| September 22, 2026 | 5.146 |
| September 21, 2026 | 5.199 |
| Date | Value |
|---|---|
| September 18, 2026 | 5.648 |
| September 17, 2026 | 5.641 |
| September 16, 2026 | 5.448 |
| September 15, 2026 | 5.555 |
| September 14, 2026 | 5.675 |
| September 11, 2026 | 5.626 |
| September 10, 2026 | 5.748 |
| September 09, 2026 | 5.820 |
| September 08, 2026 | 5.899 |
| September 04, 2026 | 6.087 |
| September 03, 2026 | 6.206 |
| September 02, 2026 | 6.109 |
| September 01, 2026 | 5.894 |
| August 31, 2026 | 5.921 |
| August 28, 2026 | 5.958 |
| August 27, 2026 | 6.042 |
| August 26, 2026 | 6.164 |
| August 25, 2026 | 6.356 |
| August 24, 2026 | 6.129 |
| August 21, 2026 | 6.105 |
| August 20, 2026 | 6.027 |
| August 19, 2026 | 6.071 |
| August 18, 2026 | 5.971 |
| August 17, 2026 | 5.862 |
| August 14, 2026 | 5.994 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| AstraZeneca PLC | 11.24 |
| GSK Plc | 4.383 |
| Johnson & Johnson | 7.789 |
| Eli Lilly & Co. | 35.39 |
| Merck & Co., Inc. | 8.552 |
Price to Book Value Related Metrics
| PE Ratio | 9.544 |
| PS Ratio | 3.374 |
| PEG Ratio | 0.7574 |
| Price to Free Cash Flow | 23.09 |
| Price | 39.05 |
| Earnings Yield | 10.48% |
| Market Cap | 130.66B |
| PEGY Ratio | 0.5549 |
| Operating PE Ratio | 7.436 |
| Normalized PE Ratio | 9.174 |